MaronDJFazioSLintonMRF. Current persectives on statins. Circulation2000;101: 207–13.
2.
ChongPHSeegerJDFranklinC. Clinically relevant differences between the statins: Implications for therapeutic selection. Am J Med2001;111: 390–400.
3.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Scandinavian Simvastatin Survival Study Group. Lancet1994;344: 1383–9.
4.
ShepherdJCobbeSMFordIIslesCGLorimerARMacFarlanePWPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995;333: 1301–7.
5.
SacksFMPfefferMAMoyeLARouleauJLRutherfordJDColeTGThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med1996;335: 1001–9.
6.
DownsJRClearfieldMWeisSWhitneyEShapiroDRBeerePAPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA1998;279: 1615–22.
7.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med1998;339: 1349–57.
8.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Heart Protection Study Collaborative Group. Lancet2002;360: 7–22.
9.
JonesPKafonekSLauroraIHunninghakeD. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol1998;81: 582–7.
10.
McAlisterFALaupacisAWellsGASackettDL. Users' guides to the medical literature XIX: Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA1999;282: 1371–7.
11.
AHFS drug information. Bethesda, MD: American Society of Health System Pharmacists, 2002.
12.
WilliamsVaughan EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol1984;24: 129–47.
13.
WilliamsVaughan EM. Classifying antiarrhythmic actions: By facts or speculation. J Clin Pharmacol1992;32: 964–77.
14.
FurbergCDPittB. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med2001;2: 205–7.
15.
FurburgCDHerringtonDMPsatyBM. Are drugs within a class interchangeable?Lancet1999;354: 1202–4.
16.
FurbergCDPittB. Are all angiotensin-converting enzyme inhibitors interchangeable?J Am Coll Cardiol2001;37: 1456–60.
17.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA2001;285: 2486–97.
18.
PearsonTA. New tools for coronary risk assessment: What are their advantages and limitations?Circulation2002;105: 886–92.
19.
CarterBL. Blood pressure as a surrogate end point for hypertension. Ann Pharmacother2002;36: 87–92.
20.
LonnE. The use of surrogate endpoints in clinical trials: Focus on clinical trials in cardiovascular diseases. Pharmacoepidemiol Drug Saf2001;10: 497–508.
21.
EllenbergSS. Surrogate endpoints: The debate goes on. Pharmacoepidemiol Drug Saf2001;10: 493–6.
22.
ThompsonDF. Surrogate end points, skepticism, and the CAST study. Ann Pharmacother2002;36: 170–1.
23.
RobinsJM. Data, design, and background knowledge in etiologic inference. Epidemiology2001;11: 313–20.
24.
HernanMAHernandez-DiazSWerlerMMMitchellAA. Causal knowledge as a prerequisite for confounding evaluation: An application to birth defects epidemiology. Am J Epidemiol2002;155: 176–84.
25.
StampferMJHuFBMansonJERimmEBWillettWC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med2000;343: 16–22.
26.
RidkerPMRifaiNClearfieldMDownsJRWeisSEMilesJSMeasurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med2001;344: 1959–65.
27.
RidkerPM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet2001;358: 946–8.
28.
ReisenWFEnglerHRischMKorteWNosedaG. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J2002;23: 794–9.
29.
SacksFMTonkinAMCravenTPfefferMAShepherdJKeechACoronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation2002;105: 1424–8.
30.
StampferMJKraussRMMaJBlanchePJHollLGSacksFMA prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA1996;276: 882–8.
31.
VaughanCJMurphyMBBuckleyBM. Statins do more than just lower cholesterol. Lancet1996;348: 1079–82.
32.
RosensonRSTangneyCC. Antithrombotic properties of statins: Implications for cardiovascular event reduction. JAMA1998;279: 1643–50.
